Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lilly’s lebrikizumab with topical corticosteroids improved atopic dermatitis in the study

By Brian Buntz | April 11, 2022

Eli LillyEli Lilly (NYSE:LLY) has announced promising results from a Phase 3 study of patients with moderate-to-severe atopic dermatitis (AD).

At 16 weeks, 70% of patients with moderate-to-severe atopic dermatitis (AD) taking both lebrikizumab and standard-of-care topical corticosteroids (TCS) achieved at least 75% improvement in overall disease severity (EASI-75*) in the ADhere trial.

The company made the announcement at the fourth annual Revolutionizing Atopic Dermatitis (RAD) Conference.

The combination of lebrikizumab, an experimental investigational interleukin (IL)-13 inhibitor, and topical corticosteroids also resulted in itch symptoms, sleep and quality of life compared with placebo and topical steroids.

“Today’s ADhere data, together with results from the ADvocate monotherapy studies, demonstrate the potential for lebrikizumab to reduce disease burden and provide relief for people with uncontrolled atopic dermatitis when used either alone or combined with topicals,” said Dr. Eric Simpson, professor of dermatology and director of clinical research at Oregon Health & Science University in Portland, and principal investigator of ADhere. “Lebrikizumab specifically targets the IL-13 pathway, which plays the central role in this chronic inflammatory disease,” Simpson said in a statement. “These results strengthen our understanding of lebrikizumab in atopic dermatitis and help establish it as a possible new treatment option.”

Sanofi and Regeneron have won FDA approval for Dupixent (dupilumab), a biologic blocking IL- 4 and IL-13 for atopic dermatitis.

Dupixent is also indicated for some asthma patients and as an add-on maintenance treatment for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis.

IL-13 is involved in Type 2 inflammation in atopic dermatitis.

In the ADhere trial, 41% of patients receiving lebrikizumab and topical corticosteroids achieved clear or almost clear skin (IGA) at 16 weeks. Conversely, 22% of patients taking placebo plus topical steroids achieved the same benchmark.

 


Filed Under: Biologics, Dermatology
Tagged With: dupilumab, Dupixent, lebrikizumab, Lilly
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
Sanofi ramps up distribution of Beyfortus ahead of RSV season
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE